Lipum has developed a new biological drug candidate that will become the first in a completely new class of drugs for the treatment of chronic inflammatory diseases. The drug candidate, named SOL-116, is a therapeutic antibody, and the company’s initial focus is on offering it as a treatment for rheumatism in adults and children. This involves making preparations for clinical trials that are due to begin in 2022.
The company is preparing a listing on the Nasdaq First North Growth Market with the help of a funding round to attract new capital. G&W Fondkommission assists Lipum in this process.
“Up to this point we have been financed through private capital and grants from both Vinnova and the EU’s Horizon 2020 program. Now we are facing the next exciting step in the company’s development. For us it is the perfect time to gain access to the capital markets with a listing”, says Einar Pontén.
For further information please contact:
Einar Pontén, CEO
+46 70 578 34 95
Lipum is a biopharmaceutical company specialising in the discovery and development of new treatments for chronic inflammatory diseases. The drug candidate SOL-116 is a humanized antibody that aims to provide safer and more effective treatment by blocking a previously overlooked target molecule (BSSL) in the immune system. SOL-116 is in a late preclinical phase with convincing data for the rare disease pediatric rheumatism as well as rheumatoid arthritis. Lipum is also evaluating a number of other inflammatory diseases where there is significant need for treatments. The company is highly experienced in operational and administrative processes and is well positioned for the next phase of growth. Lipum has operations based in Umeå in northern Sweden, which is home to one of the country’s leading life science clusters. The company’s discovery has received international attention and a significant grant from the EU via the Horizon 2020 program.